Tyloxapol

Drug Profile

Tyloxapol

Alternative Names: SuperVent

Latest Information Update: 24 Nov 2003

Price : $50

At a glance

  • Originator Charlotte-Mecklenberg Hospital Authority
  • Developer Charlotte-Mecklenberg Hospital Authority; Discovery Laboratories; University of Utah
  • Class Expectorants; Surfactants
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bronchitis; Cystic fibrosis

Most Recent Events

  • 24 Nov 2003 Discontinued - Phase-I for Bronchitis in USA (Inhalation)
  • 24 Nov 2003 Discontinued - Phase-II for Cystic fibrosis in USA (Inhalation)
  • 11 Apr 2000 A clinical study has been added to the adverse events and pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top